This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.  Read our Cookies Policy.
Close
Eye News
  • Features
    • Close
    • Features
    • Allied Professions
    • Humanitarian
    • Interviews
    • AI & Oculomics
    • Ophthalmology
    • Optometry
    • Podcast videos
    • Supplements
  • Education
    • Close
    • Education
    • Learning Curve
    • Quiz
    • Top Tips
    • Trainees
    • Medico-Legal
    • The Truth Behind The Headlines
    • Case Reports
    • Pete's Bogus Journey
  • Reviews
    • Close
    • Reviews
    • Book Reviews
    • Journal Reviews
    • What's trending?
    • Tech Reviews
    • My Top Five
    • The Culture Section
  • Events
  • News
  • Product Guide
  • Industry News
  • Contact us
    • Close
    • Contact us
    • Write for Eye News
  • Home
  • Features
  • Ophthalmology
  • Identifying drugs associated with intraoperative floppy iris syndrome

Identifying drugs associated with intraoperative floppy iris syndrome
By Hariharan Narendran

1 April 2016 | Hariharan Narendran | EYE - Cataract, EYE - Refractive
Share This

 

Before David Chang MD from the University of California found out about intraoperative floppy iris syndrome (IFIS), ophthalmologists were mystified each time they came across cataract surgeries that were characterised by sudden intraoperative iris prolapse and pupil constriction. The biggest predicament being that an ophthalmologist is not likely to anticipate such challenges so an encounter with IFIS during a procedure can only disrupt the process and ultimately disadvantage the quality of care provided.

Fortunately, David Chang MD discovered the association between alpha-1-antagonist and this syndrome. It was ultimately named IFIS. IFIS can significantly increase the probability of complications post-surgery particularly if not recognised, understood and anticipated. The complications include sight-threatening phenomena such as severe iris defects, which are associated with permanent pupil deformity, glare and photophobia.

The audit

Since the process of recognising IFIS is a major component of the initiative to reduce complications associated with IFIS, I conducted a clinical audit on a number of ophthalmologists in Glasgow during the Ophthalmology Clinical Governance Meeting in May 2015. The title of this audit was ‘Auditing the Ability of Ophthalmologists to Identify Drugs that are Associated with IFIS’. A list of 20 different drugs were presented to 35 different ophthalmologists. There were 12 drugs associated with IFIS, while the other eight drugs were distractors.

The average score for the first audit in May was 10.59, while the average score for the re-audit in August, which successfully completed the audit cycle, was 12.46. In order to increase awareness among healthcare professionals in general, a list of drugs associated with IFIS was displayed within all clinical rooms in Stobhill Hospital, Gartnavel Hospital and Glasgow Royal Infirmary.

It should, however, be noted, Tamsulosin was well recognised by all the ophthalmologists who were audited. Tamsulosin continues to be the major cause of IFIS and it was gratifying to see this being well appreciated. In July 2008, the two largest global ophthalmology organisations, the ASCRS and the American Academy of Ophthalmology issued a joint IFIS education update statement asking prescribing physicians to consider involving an ophthalmologist before initiating an alpha-1- antagonist in patients with known cataracts. Physicians should also remind patients already taking these drugs to report this medication history before having any eye surgery.

“IFIS can significantly increase the probability of complications post-surgery particularly if not recognised, understood and anticipated.”

A quick search on the Royal Pharmaceutical Society website showed that IFIS was mentioned under ‘special warnings / precautions’ for prescribing Tamsulosin. However, this was not always the case for the other drugs listed here.

In conclusion, although the awareness of drugs that cause IFIS appears to be good, there will always be room for improvement. In my opinion, an online method should be created to flag up any drug that may cause IFIS which might be on the patient’s list of medication. This would enable the ophthalmologist to be fully prepared. However, this would require the collaborative effort of all healthcare professionals including general practitioners, physicians (who prescribe Tamsulosin for benign prostate hyperplasia) and ophthalmologists.


The list of drugs associated with intraoperative floppy iris syndrome:

  • Alfuzosin
  • Chlorpromazine
  • Donepezil
  • Doxazosin
  • Finasteride
  • Labetolol Hydrochloride
  • Mianserin
  • Prazosin
  • Risperidone
  • Ropinirole
  • Saw Palmetto
  • Silodosin
  • Tamsulosin
  • Terazosin

 

 

Acknowledgements

The author would like to thank all participants, patients and staff members at Stobhill Hospital, and especially Mr Donald Montgomery for his guidance on this audit.

 

Declaration of Competing Interests: None declared.

 

 

COMMENTS ARE WELCOME

Share This
Hariharan Narendran
CONTRIBUTOR
Hariharan Narendran

University of Glasgow, UK.

View Full Profile
Originally Published
EYE NEWS VOLUME 22 ISSUE 6 APRIL/MAY 2016
Download the full article
Download Article

Top Of Page

9 Gayfield Square, 
Edinburgh EH1 3NT, UK.

Call: +44 (0)131 557 4184
www.pinpoint-scotland.com

WEBSITE DETAILS
  • Cookie Policy
  • Data Protection Notice
  • Privacy Policy
  • Terms and Conditions
ABOUT US
  • Who we are
  • Register
  • Contact us
  • Contributors
  • Company Awards
DIGITAL ISSUES/GUIDELINES
  • Digital issues - Library
  • Supplements - Library
  • Guidelines
Accreditations
IPSO_FLAG_TEAL 2025.png cpdcertified.png

Pinpoint Scotland Ltd (Registered in Scotland No. SC068684) | © 2025 - Website by Gecko Agency